Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
883.20
-7.48 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients
July 29, 2021
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (...
Via
Benzinga
Is This Mid-Cap Biotech Stock a Buy Now?
July 29, 2021
This mid-cap growth stock could be a long-term winner.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Market Briefing For Thursday, July 29
July 29, 2021
Disarming SARS-CoV-2 with pharmaceutical drugs is the 'holy grail' to end the COVID-19 panic, and generally eliminate the panic pressures for vaccines.
Via
Talk Markets
Exposures
COVID-19
3 Things About Regeneron That Smart Investors Know
July 29, 2021
The biotech's COVID-19 antibody cocktail made headlines last year, but there's a bigger story here.
Via
The Motley Fool
Topics
Government
Exposures
COVID-19
Political
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
July 27, 2021
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap.
Via
The Motley Fool
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
July 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...
Via
Benzinga
Maravai Lifesciences Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
July 23, 2021
Maravai Lifesciences sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers
July 22, 2021
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all...
Via
Benzinga
Alnylam Pharmaceuticals Stock Sees Healthy Rising Relative Strength Rating
July 19, 2021
The Relative Strength (RS) Rating for Alnylam Pharmaceuticals stock climbed into a new percentile Monday, as it got a lift from 63 to 71.
Via
Investor's Business Daily
C4 Therapeutics Stock Enters Leadership Territory
July 19, 2021
A Relative Strength Rating upgrade for C4 Therapeutics shows improving technical performance.
Via
Investor's Business Daily
AMD And Biogen Lead The QQQ Lower Thursday
July 15, 2021
U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel. ...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
5 French Stocks To Consider For Bastille Day
July 14, 2021
Bastille Day is France’s National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept...
Via
Benzinga
Is This Coronavirus Stock Undervalued?
July 14, 2021
This biotech giant might be down, but it isn't out just yet.
Via
The Motley Fool
Exposures
COVID-19
2 Biotech Stocks That are Dirt Cheap Right Now
July 13, 2021
Biotech companies responded to the COVID-19 pandemic in a remarkable way, with vaccinations, treatments, diagnostics, and variant monitoring.
Via
Talk Markets
Exposures
COVID-19
3 Top Biotech Stocks to Buy in July
July 11, 2021
Now's the time to get into these companies while their valuation is still favorable.
Via
The Motley Fool
Is It Too Late to Buy Intellia Therapeutics?
July 10, 2021
After skyrocketing 68% last week, will this stock keep running higher?
Via
The Motley Fool
Here's Why Regeneron Gained 11% Last Month
July 07, 2021
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands.
Via
The Motley Fool
Will an Increase in Vaccinations Hurt Regeneron's COVID Treatment Sales?
July 05, 2021
The antibody cocktail treats people with mild-to-moderate illness.
Via
The Motley Fool
Topics
Cannabis
Exposures
COVID-19
Cannabis
This News May Mean Billions for Regeneron
July 05, 2021
Regeneron's COVID-19 treatment is getting easier to administer -- and produce.
Via
The Motley Fool
Topics
Cannabis
Exposures
COVID-19
Cannabis
3 Tips for Coronavirus Investing Right Now
July 05, 2021
Whether you're a cautious or aggressive investor, there's something for you in this space.
Via
The Motley Fool
Topics
Cannabis
Exposures
COVID-19
Cannabis
Regeneron Discovers GPR75 Gene Mutations Can Protect Against Obesity, Begins Search For New Drugs
July 02, 2021
A team at Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now, drug...
Via
Benzinga
Facebook And Nvidia Lead The QQQ Thursday
July 01, 2021
U.S. indices are trading higher following better-than-expected jobless claims, which lifted recovery sentiment to start off July. ...
Via
Benzinga
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
June 30, 2021
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,...
Via
Benzinga
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
June 30, 2021
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
Via
The Motley Fool
Exposures
COVID-19
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
June 29, 2021
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial...
Via
Benzinga
Exposures
COVID-19
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
June 29, 2021
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
June 29, 2021
Upgrades For Nutrien Ltd (NYSE:
Via
Benzinga
Is Now The Time To Buy Stock In Tesla, GM Or Regeneron?
June 29, 2021
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I...
Via
Benzinga
Intellia Seeks To Raise $400M Via Equity
June 29, 2021
Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to...
Via
Benzinga
Facebook And Nvidia Lead The QQQ Higher Monday
June 28, 2021
The Nasdaq was trading sharply higher throughout Monday’s session amid a rebound in growth and tech names. The Inve...
Via
Benzinga
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.